Thompson Rahsaan, Chief Legal and Compliance officer at Zevra Therapeutics ($ZVRA), sold common shares on the open market twice in the past year for a total of $257,000. His most recent sale occurred on January 30, 2026. These ZVRA insider sales rank 7,893rd among 11,678 individuals in our database, well below the average of $8.6 million and 6.4 transactions per insider. He made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 30, 2026 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Thompson Rahsaan | Chief Legal & Compliance | M | Common Stock | 11333 | $0.00 | 53,999.0000 | 56,783,000 | 26.56% | 0.02% |
| Jan. 30, 2026 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Thompson Rahsaan | Chief Legal & Compliance | M | Restricted Stock Unit | 11333 | $0.00 | 22,667.0000 | 56,783,000 | 33.33% | 0.02% |
| Jan. 29, 2026 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Thompson Rahsaan | Chief Legal & Compliance | A | Stock Option (right to buy) | 75000 | $0.00 | 75,000.0000 | 56,783,000 | 9999.99% | 0.13% |
| Jan. 29, 2026 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Thompson Rahsaan | Chief Legal & Compliance | A | Restricted Stock Unit | 37500 | $0.00 | 37,500.0000 | 56,783,000 | 9999.99% | 0.07% |
| Jan. 30, 2026 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Thompson Rahsaan | Chief Legal & Compliance | S | Common Stock | 4080 | $8.83 | 49,919.0000 | 56,783,000 | 7.56% | 0.01% |
| June 26, 2025 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Thompson Rahsaan | Chief Legal & Compliance | S | Common Stock | 24000 | $9.21 | 42,666.0000 | 47,808,817 | 36.00% | 0.05% |
| June 21, 2025 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Thompson Rahsaan | Chief Legal & Compliance | M | Restricted Stock Unit | 66666 | $0.00 | 133,334.0000 | 47,808,817 | 33.33% | 0.14% |
| June 21, 2025 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Thompson Rahsaan | Chief Legal & Compliance | M | Common Stock | 66666 | $0.00 | 66,666.0000 | 47,808,817 | 9999.99% | 0.14% |
| Jan. 30, 2025 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Thompson Rahsaan | Chief Legal & Compliance | A | Restricted Stock Unit | 34000 | $0.00 | 34,000.0000 | 47,808,817 | 9999.99% | 0.07% |
| Jan. 30, 2025 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Thompson Rahsaan | Chief Legal & Compliance | A | Stock Option (right to buy) | 68000 | $0.00 | 68,000.0000 | 47,808,817 | 9999.99% | 0.14% |
| June 21, 2024 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Thompson Rahsaan | Chief Legal & Compliance | A | Restricted Stock Unit | 200000 | $0.00 | 200,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 24, 2023 | Lyell Immunopharma, Inc. | $LYEL | Thompson Rahsaan | Chief Legal Officer | A | Option (right to buy) | 245000 | $0.00 | 245,000.0000 | 0 | 9999.99% | 0.00% |